HUMANIGEN: OWS support and enrolment expansion bode well for phase III readout, now in 1Q21 | BUY | USD30
HUMANIGEN - BUY | USD30OWS support and enrolment expansion bode well for phase III readout, now in 1Q21
Lenzilumab gets the endorsement from OWS
With hitting ‘promising zone’, Humanigen is expanding target enrolment of the phase III
Timing for the expected phase III readout is pushed into Q1 2021
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.